Innovative Pathways in Lung Cancer Screening with CyPath® Lung Test

The CyPath® Lung Test is a noninvasive, AI-assisted sputum assay that could alter outpatient lung‑nodule workflows by enabling earlier detection in small pulmonary nodules and delivering an actionable result to guide the next diagnostic step.

Current CT‑based screening and nodule workups often rely on serial imaging or invasive biopsy for small or indeterminate lesions, producing diagnostic delay and patient anxiety. A noninvasive molecular triage offers an intermediate option that may reduce uncertainty and shorten time to definitive diagnosis. In practice, the assay could sit between low‑yield surveillance and invasive sampling, clarifying risk and reducing unnecessary immediate interventions.

The assay analyzes sputum and uses flow cytometry and AI to identify malignant cell populations. bioAffinity Technologies reports promising sensitivity and specificity for early‑stage disease in high‑risk patients with small nodules.

Cases involving successful identification of stage 1a lung cancer will be presented at the American Cancer Society National Lung Cancer Roundtable.